correlated with the protective activity but not with the binding intensity of MH-4H7 to the organisms. In addition, burned and leukopenic mice as well as normal mice infected with serotype G strains recovered from a very low dosage of MH-4H7. Thus, a monoclonal antibody directed to the outer core region of P. aeruginosa lipopolysaccharide was effective against infection with a wide range of 0-serotype strains of P. aeruginosa.
Pseudomonas aeruginosa is a major pathogen for opportunistic infections in compromised hosts such as patients undergoing immunosuppressive therapy and those with burns, diffuse panbronchiolitis, or cystic fibrosis. Chemotherapy in such patients is often ineffective because the resistance of P. aeruginosa strains to many kinds of antibiotics has been increasing (3, 12, 16) . In contrast, immunotherapy has been suggested (4, 15, 17, 19) to reduce infectivity of P. aeruginosa. Lipopolysaccharide (LPS), mucoid exopolysaccharide, flagella, and outer membrane protein F of P. aeruginosa have been extensively studied for their effectiveness as protective antigens (1, 6, 9, 14) . Recently, monoclonal antibodies (MAbs) specific for LPS have been obtained and shown to be highly protective (2, 18, 21, 22, 25, 26, 29) .
LPS consists of three regions, 0 polysaccharide, core oligosaccharide, and lipid A, which are covalently bound to each other. Antibodies to 0 polysaccharide have been demonstrated to be more effective than antibodies to the other components of LPS in experimental animal infection models (13, 18, 21, 22, 25) . However, the former antibodies have narrow efficacy spectra, because each of them is only effective against strains belonging to the specific 0 serotype that is recognized by the antibody.
We have recently isolated human MAbs MH-4H7 and KN-2B11, which are thought to recognize the outer core region of P. aeruginosa LPS, especially the nonreducing terminal of the L-rhamnose residue in the outer core region, and we have demonstrated that the MAbs bind to strains of several serotypes (27) . In this study, we examined the effects of MH-4H7 against infections in mice caused by some * Corresponding author.
clinical isolates belonging to various serotypes of P. aeruginosa. (27) was produced by culturing the heterohybridoma cell line MH-4H7 in a serum-free medium, Celgrosser H (Sumitomo Parmaceuticals, Osaka, Japan), that contained only insulin (5 mg/liter) and transferrin (5 mg/liter) as protein components. The preparation chromatographically purified to more than 95% purity was used for this study.
MATERIALS AND METHODS

MH-4H7. MH-4H7 (immunoglobulin
Fluorescein isothiocyanate labeling of MH-4H7. The MAb (5 mglml) was incubated with 20 ,ug of fluorescein isothiocyanate isomer I (Dojin Chemical Laboratory, Kumamoto, Japan) per ml in 0.05 M sodium-hydrogen-carbonate buffer (pH 9.5) containing 0.85% sodium chloride at 4°C for 4 h. Then the labeled MAb was separated by gel chromatography on a PD-10 Sephadex G-25M column (Pharmacia, Uppsala, Sweden) in phosphate-buffered saline (PBS).
Bacterial strains. P. aeruginosa IIDlOOl (serotype A) was obtained from the Institute of Medical Science, University of Tokyo, Tokyo, Japan. Clinical isolates used for this study were from our laboratory collection. The serotypes of strains were determined by a serotype grouping kit, Mei-assay (Meiji Seika Co., Tokyo, Japan). All strains were grown on heart infusion agar (Nissui Pharmaceuticals, Tokyo, Japan) at 370C.
Binding assay. The binding specificity of MH-4H7 to these clinical isolates was tested by an enzyme-linked immunosorbent assay previously described in detail (27) Protection experiments in mice. In the following three experimental infection models with P. aeruginosa, male ICR mice (Japan SLC Inc.) 4 weeks old (body weight, 22 to 24 g) were used. Each of the 10 mice per group was infected with four different inoculum sizes of fivefold serial dilutions. Serial 10-fold-diluted MH-4H7 (0.01 to 10 ,ug per mouse) was i.p. or intravenously (i.v.) administered.
The animals were observed for 6 days. The lethal dosage causing death in 50% of mice (LD50) was calculated by probit analysis. The significance of differences from control group was indicated by nonoverlapping 95% confidence intervals. 
The binding activity of MH-4H7 was tested at a concentration of 1 ,ug/ml. This activity was expressed as A405 for an enzyme-linked immunosorbent assay in which plates coated with glutaraldehyde-fixed P. aeruginosa cells were used.
b The minimum concentration (micrograms per milliliter) of MH-4H7 required for agglutinating viable P. aeruginosa cells (approximately 5 x 108 CFU/ml).
' The ability of MH-4H7 to promote the uptake and killing of P. aeruginosa by mouse resident peritoneal macrophages in the presence of complement was measured. The opsonophagocytic activity was expressed as the highest percentage of bacterial cells killed.
There was no significant difference in LD50 between BSAtreated groups and untreated groups.
(i) Normal mouse model. A cell suspension of each bacterial strain was serially diluted in saline and mixed with bacteriological mucin (Difco Laboratories, Detroit, Mich.). The bacterial suspension (0.2 ml) containing 5% mucin was injected into mouse peritoneum. One hour later, 0.2 ml of MAb in PBS was administered to the mice either i.p. or i.v. Negative control groups of mice were either untreated or injected with BSA instead of MAb.
(ii) Leukopenic mouse model. Leukopenic mice were prepared by i.p. administration of 250 mg of cyclophosphamide (Shionogi Pharmaceuticals Co. Ltd., Osaka, Japan) per kg of body weight. Four days after the treatment, when the total leukocyte number was less than 500 per mm3, mice were i.p. challenged with the bacterial suspension in the presence of 5% mucin; 1 h later, MAb was administered i.p. or i.v.
(iii) Burned mouse model. Burned mice were prepared by the procedure of Stieritz and Holder (24) with a slight modification. After anesthesia, an 8-cm2 burn was created on the shaved backs of mice with an ethanol flame. Immediately after 10 s of burning, saline (0.3 ml) was injected i.p. for fluid replacement, and the bacterial suspension in saline (0.2 ml) was inoculated subcutaneously at the burn site. One hour later, MAb in PBS (0.2 ml) was i.v. administered.
RESULTS
In vitro activities. Human MAb MH-4H7 specifically bound to standard strains and clinical isolates of P. aeruginosa Homma serotype A, F, G, H, K, and M strains in the enzyme-linked immunosorbent assay, but it did not bind to serotype B, E, or I strains at all (Table 1) (27) .
The binding specificity (spectrum) with glutaraldehydefixed cells in the enzyme-linked immunosorbent assay was (Fig. 1) . The opsonophagocytic killing activity was dependent upon the concentration of MH-4H7. The absence of either MX or MAb resulted in no killing effect. Serotype G strains were more sensitive to killing by the MAb than were serotype A, H, K, and F strains ( Fig. 1 In vivo activities. The protective activities of MH-4H7 were evaluated in three kinds of experimental mouse models.
In normal mice i.p. challenged with P. aeruginosa clinical isolates, MH-4H7 i.p. administered 1 h after the bacterial challenge at a dosage of 0.1 jig per mouse significantly (P < 0.05) protected mice against all strains of serotype G tested except for strain SP9785 (Table 2) . For example, with MH-4H7 (0.1 jig per mouse) the LD50 of strain SP9792 was 32-fold higher (1.6 x 107 CFU) than that of the control. MH-4H7 (1.0 jig per mouse) also significantly (P < 0.05) protected mice against infections by strains of serotypes A, H, K, and F. In contrast, MH-4H7 (1.0 jig per mouse) had no efficacy against serotype M strains or against serotype B, E, and I strains.
The protective activity was dependent upon the concentration of MH-4H7 (Fig. 2) . More than 0.01 jig of the MAb per mouse significantly (P < 0.05) protected against challenge with SP9792 (7 to 12 LD50s) (Fig. 2B) (Fig. 3) . The i.v. administered MAb showed the same magnitude of efficacy as did the i.p. administered MAb against strains of sensitive serotypes (data not shown).
In leukopenic mice, 50% of which were killed by challenge (Table 3) .
To address the question of how MH-4H7 displays its protective activity, we quantitated the P. aeruginosa in the peritoneum and blood at various times after the infection with SP9792 organisms in the normal mouse model (Fig. 4) . In the peritoneums of mice that did not receive MH-4H7, the number of viable bacteria was constant until 4 to 6 h after infection and then bacteria multiplied exponentially. In the case of mice that received MH-4H7 (0.1 ,ug per mouse), however, the number of viable bacteria rapidly decreased within 1 h after the administration of MAb and was under the limit of detection 7 h after the administration of MAb (Fig.   4A ). Approximately 104 CFU of bacteria per ml were detected in the blood 2 h after infection in both MAb-treated and untreated mice, but no bacteria could be detected 4 h after infection in MAb-treated mice, in contrast to rapid proliferation of bacteria in untreated mice (Fig. 4B) .
DISCUSSION
Antisera and MAbs reactive with the 0 polysaccharide of P. aeruginosa LPS have been reported to act as opsonins and effectively protect mice from death caused by experimental bacteremia (11, 21, 22, 25, 29) . Almost all of the antibodies so far reported were directed to serotype-specific epitopes on LPS and were only active against a specific serotype out of 17 serotypes. Lang et al. (11) recently reported MAbs that recognized and had protective activity against two or more Fisher immunotypes of P. aeruginosa. These MAbs are likely to recognize the epitopes in the In a leukopenic mouse model, mice were administered with cyclophosphamide (250 mg/kg) and challenged with bacteria 4 days later; then 0.1 pg of MH4H7 was administered i.p. 1 h after bacterial challenge. In O-polysaccharide region of LPS shared by several immunotypes of P. aeruginosa.
In contrast, there have been no reports on protective MAbs that have been directed to the outer core region of P. aeruginosa LPS. Coughlin and Bogard only reported that murine MAbs specific for the outer-core polysaccharide were immunoprotective against infections by Escherichia coli (5).
We previously described (27) the production and characterization of human MAb MH-4H7, directed to the outer core region of P. aeruginosa LPS. MH-4H7 bound in vitro to several serotypes of P. aeruginosa, such as serotypes A, F, G, H, K, and M. The epitope on LPS recognized by the MAb was supposed to be L-rhamnose and its neighboring residue in the outer core region. In this paper we have first demonstrated that MH-4H7 protected mice in vivo significantly against a challenge with clinical isolates of Homma serotypes A, F, G, H, and K but not with serotype M strains ( Table 2) .
What kinds of factors determine the immunoprotective activity of MAbs against bacterial infections? To address the question, we examined the binding, agglutinating, and opsonophagocytic activities of MH-4H7 against 15 to 17 strains over nine serotypes compared with its in vivo protective activity. MH-4H7 was more effective in vivo against serotype G strains than against serotype A, F, H, and K strains, in accordance with the observation that opsonophagocytic activity, expressed as the reduction rate of viable bacteria in the presence of the MAb, complement, and macrophages, was higher against serotype G strains (more than 90%) than against serotype A strains (60 to 80%) and serotype F, H, and K strains (50 to 86%). The protective activity of the MAb was more related with the opsonophagocytic activity rather than its binding and agglutinating activities (Table 1 and 2), suggesting that the opsonophagocytic activity would greatly contribute to the protection of MH-4H7 against pseudomonal infections.
Although MH-4H7 agglutinated all three strains of serotype M tested, it showed neither protective nor opsonophagocytic activity. Neither mucoid products nor elastase secreted by P. aeruginosa was involved in these low MAb activities (data not shown). Therefore we do not yet know the real reason why serotype M strains were resistant to the opsonophagocytic activity of MH-4H7. Opsonophagocytosis of MH-4H7 was complement dependent. Pier et al. (19, 20) have also reported that IgM requires complement for phagocytic killing. Recently, Schiller and Joiner (23) and Engels et al. (7, 8) reported that some strains of P. aeruginosa could not fix complement 3b to their surface although they activated complement 3. This phenomenon might answer the question of why serotype M strains were not well phagocytized. Wild strains of P. aeruginosa have a smooth type of LPS consisting of both high-and low-molecular-weight LPS. High-molecular-weight LPS seems to have a long 0-polysaccharide chain. Hence we were afraid that HMW LPS would interfere with the access of the MAb to the inner target, resulting in low protective activity. However, we have demonstrated that this is not the case, because MH-4H7 bound to viable cells of susceptible strains in vitro and was also protective against them in vivo. Interestingly, Kelly et al. (10) recently reported that cells grown in vivo appeared to lack a series of high-molecular-weight LPSs compared with cells grown in vitro and to have gained a new series of low-molecular-weight LPSs. This may mean that under some conditions, cells in vivo become enriched in the rough-natured cell population that is highly sensitive to the MAb.
Human MAbs to the 0 polysaccharide of P. aeruginosa have been shown to have potent efficacy against experimental infection models in normal mice by several laboratories.
For example, the PD50s were reported to range from 0.2 to 10 ,ug per mouse (10 to 500 ,ug/kg) for IgG (21) and 0.5 to 3 ,ug per mouse (25 to 150 ,ug/kg) for IgM under a relatively mild challenge of 5 LD50s (26). 0 polysaccharide-specific human MAbs of IgG and IgM isolated by us also showed PD50s ranging from 0.8 to 2.5 ,ug per mouse (data not shown). The PD50s in the neutropenic mouse model were also reported to range from 0.3 to 0.5 ,ug per mouse for IgM and IgG (20) . Compared with 0 polysaccharide-specific human MAbs, MH-4H7 showed a more potent protective activity against infections with serotype G strains (their PD50s were 0.01 to 0.1 ,ug per mouse against a challenge of 8 to 22 LD50s) and a comparable activity against serotype A strains (their PD50s ranged from 3 to 8 ,ug per mouse against a challenge of 7 to 12 LD50s and 0.04 to 0.1 p,g per mouse against a challenge of 2 to 5 LD50s). MH-4H7 strongly promoted the clearance of challenge bacteria from the peritoneal cavity and blood of mice, as shown in Fig. 4 . A preliminary pharmacokinetic study demonstrated that the level (in serum) of MH-4H7 administered to mice at the effective dose reached and maintained a sufficient concentration to promote phagocytosis for 30 h (data not shown), which may explain the potent protective activity of MH-4H7.
In this study we showed the efficacy of MH-4H7 in experimental infection models with several serotypes of P. aeruginosa. These results suggest its potential usefulness for immunotherapy in clinics.
